Surfactant Protein D Levels in GCF Before and After MINST in Periodontitis
Evaluation of Surfactant Protein D (SP-D) Levels in the GCF of Periodontitis Patients Associated With the Endpoints After Minimally Invasive Non-surgical Periodontal Therapy: A Before and After Study
This study will evaluate changes in Surfactant Protein D (SP-D) levels in gingival crevicular fluid (GCF) of patients with periodontitis before and after minimally invasive non-surgical periodontal therapy (MINST).
Participants diagnosed with stage II or III periodontitis will receive minimally invasive non-surgical periodontal treatment. GCF samples will be collected at baseline and 6 months after treatment, and SP-D levels will be measured using enzyme-linked immunosorbent assay (ELISA).
The study will also assess clinical periodontal outcomes, including full-mouth plaque score, full-mouth bleeding score, probing pocket depth, clinical attachment level, gingival recession, and patient satisfaction. Each participant will serve as their own control by comparing baseline values with 6-month post-treatment values.
Visão geral do estudo
Status
Intervenção / Tratamento
Descrição detalhada
Periodontitis is a chronic multifactorial inflammatory disease characterized by progressive destruction of the supporting periodontal tissues. Conventional clinical parameters, such as probing pocket depth, bleeding on probing, and clinical attachment level, are useful for diagnosis and follow-up but may reflect tissue destruction after it has already occurred. Therefore, biomarkers that reflect the biological inflammatory status of periodontal tissues may improve monitoring of disease activity and treatment response.
Surfactant Protein D (SP-D) is an innate immune molecule involved in host defense and modulation of inflammation. It has been detected in oral fluids, including gingival crevicular fluid, and may be associated with periodontal inflammation. This study aims to evaluate whether SP-D levels in GCF change after minimally invasive non-surgical periodontal therapy in patients with periodontitis.
This is a single-group before-and-after interventional clinical study. Eligible participants with stage II or III periodontitis will be recruited from the outpatient periodontal clinics of the Faculty of Dentistry, Cairo University. At baseline, periodontal clinical parameters will be recorded, including full-mouth plaque score, full-mouth bleeding score, probing pocket depth, clinical attachment level, and gingival recession. GCF samples will be collected from selected periodontal sites using sterile paper strips and stored until biochemical analysis.
All participants will receive minimally invasive non-surgical periodontal therapy, including oral hygiene instructions, supragingival plaque control, and subgingival instrumentation using minimally invasive techniques. Treatment will be performed using fine periodontal instruments, thin ultrasonic tips, magnification when available, and local anesthesia when needed to improve patient comfort and minimize tissue trauma.
After 6 months, participants will be recalled for clinical re-evaluation and collection of post-treatment GCF samples from the same sites. SP-D levels will be measured using ELISA. The primary outcome will be the change in SP-D level from baseline to 6 months after treatment. Secondary outcomes will include changes in plaque score, bleeding score, probing pocket depth, clinical attachment level, gingival recession, and patient satisfaction.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Hossam Ashraf ElMasry
- Número de telefone: +201129559757
- E-mail: hossam.eldamarany@dentistry.cu.edu.eg
Locais de estudo
-
-
-
Cairo, Egito, 12613
- Recrutamento
- Faculty of Dentistry, Cairo University
-
Contato:
- Faculty of Dentistry, Cairo University
- Número de telefone: 01002159535
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Male and female participants aged 18 years or older.
- Diagnosis of periodontitis, classified as stage II or stage III according to the 2018 classification system.
- Presence of at least one tooth with probing pocket depth (PPD) of 5 mm or more, clinical attachment loss (CAL), and radiographic evidence of bone loss.
- Presence of at least one intrabony defect with a radiographic intrabony component measuring 3 mm or more.
Exclusion Criteria:
- Current smokers or individuals with a history of smoking within the past year.
- Pregnant or lactating women.
- Use of systemic antibiotics or anti-inflammatory medications within the last 3 months.
- Known allergy to any materials or agents used during periodontal therapy.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: MINST Group
Participants diagnosed with periodontitis will receive minimally invasive non-surgical periodontal therapy (MINST).
Clinical periodontal parameters and gingival crevicular fluid samples will be collected at baseline and 6 months after treatment to assess changes in SP-D levels and periodontal outcomes.
|
Minimally invasive non-surgical periodontal therapy will include oral hygiene instructions, supragingival plaque control, and subgingival instrumentation using fine periodontal instruments, miniature Gracey curettes, thin ultrasonic tips, magnification when available, and local anesthesia when needed.
Debridement will be performed for periodontal pockets while minimizing trauma to the soft tissues.
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in Surfactant Protein D (SP-D) Levels in Gingival Crevicular Fluid
Prazo: Baseline and 6 months after treatment
|
Change in Surfactant Protein D (SP-D) concentration in gingival crevicular fluid from baseline to 6 months after minimally invasive non-surgical periodontal therapy.
SP-D levels will be measured using enzyme-linked immunosorbent assay (ELISA) and reported in ng/mL.
|
Baseline and 6 months after treatment
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in Full-Mouth Plaque Score
Prazo: Baseline and 6 months after treatment
|
Change in full-mouth plaque score from baseline to 6 months after treatment.
Plaque score will be recorded as the percentage of sites with visible plaque.
|
Baseline and 6 months after treatment
|
|
Change in Probing Pocket Depth
Prazo: Baseline and 6 months after treatment
|
Change in probing pocket depth from baseline to 6 months after treatment.
Probing pocket depth will be measured in millimeters using a UNC-15 periodontal probe.
|
Baseline and 6 months after treatment
|
|
Change in Clinical Attachment Level
Prazo: Baseline and 6 months after treatment
|
Change in clinical attachment level from baseline to 6 months after treatment.
Clinical attachment level will be measured in millimeters using a UNC-15 periodontal probe.
|
Baseline and 6 months after treatment
|
|
Change in Gingival Recession
Prazo: Baseline and 6 months after treatment
|
Change in gingival recession from baseline to 6 months after treatment.
Gingival recession will be measured in millimeters from the cemento-enamel junction to the gingival margin using a UNC-15 periodontal probe.
|
Baseline and 6 months after treatment
|
|
Patient Satisfaction Score
Prazo: 6 months after treatment
|
Patient satisfaction will be assessed at the 6-month follow-up using a standardized 5-point Likert-scale questionnaire.
Higher scores indicate greater patient satisfaction.
|
6 months after treatment
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- PER 7-2-1
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .